Slide 1: A Transformative Global R&D Collaboration
A Transformative Global R&D Collaboration July 14, 2019 1
Slide 2: Forward Looking Statements
Forward Looking Statements Galapagos This presentation may contain forward-looking statements with respect to Galapagos, including statements regarding Galapagos’ strategic ambitions, regarding the expected timing of closing of the transaction with Gilead, filings and approvals relating to the trans
Slide 3: Gilead + Galapagos Accelerating Innovation
Gilead + Galapagos Accelerating Innovation Gilead gains access to pioneering research platform and all of Galapagos’ current and future therapies outside Europe Combines Galapagos’ ability to identify novel targets with Gilead’s expertise, speed to market, and infrastructure Investment enables Galap
Slide 4: Collaboration Financial Summary
Collaboration Financial Summary $3.95 billion upfront payment $1.1 billion equity investment Gilead stake increases to Opt-in fees & certain milestones 22% and up to 29.9% if payable warrants exercised 50/50 development cost split Royalties ex-filgotinib after opt-in ranging from 20 – 24% 4
Slide 5: Current and Future Programs Summary
Current and Future Programs Summary Discovery platform Revised filgotinib GLPG1690 (IPF): GLPG1972 (OA): All other clinical • Access to pioneering collaboration license for ex- option on U.S. programs platform • 50/50 global European rights rights after Ph2b • $150M opt-in • Scientific capabilities
Slide 6: Strengthening Gilead's Pipeline
Strengthening Gilead’s Pipeline • Significant strategic advantages • Access to IP, technology, expertise and capabilities to accelerate progress in inflammation, fibrosis and multiple disease areas • Establishes a strong research base in Europe • Strengthen pipeline with first-in-class compounds • S
Slide 7: Accelerating Galapagos' Innovation to Patients
Accelerating Galapagos’ Innovation to Patients • Dramatically increase discovery & development efforts • Build European commercial infrastructure • Access to Gilead’s • Chemistry & development expertise • Commercial infrastructure & operations 7
Slide 8: Highly Productive & Versatile Target Discovery Engine
Highly Productive & Versatile Target Discovery Engine • Unique cellular assays using primary human cells • shRNA adenoviral library to silence individual genes • Wide selection of target validation tools 8
Slide 9: Accelerating Innovation
Accelerating Innovation Area Preclinical Phase 1 Phase 2 Phase 3 filgotinib 10+ indications, more Phase 2 readouts in 2019 IPF / fibrosis In Phase 3 & Phase 2 OA in US In Phase 2b Toledo / inflammation, >20 programs fibrosis, other Innovation platform; >40 clinical trials in 2019 9
Slide 10: Galapagos: Building a European Commercial Powerhouse
Galapagos: Building a European Commercial Powerhouse future collaboration 2022+ products GLPG1690 IPF filgotinib - IBD 2021 filgotinib - RA 2020 10 Note: Europe includes EU member states + Iceland + Norway + Switzerland + Lichtenstein
Slide 11: Transformative 10-Year Collaboration
Transformative 10-Year Collaboration Aimed at delivering innovation for patients Based on Galapagos’ unique discovery engine Combined with Gilead’s expertise, speed to market, and infrastructure Anticipated to accelerate development of Galapagos’ current & new programs to market 11
Slide 12: A Transformative Global R&D Collaboration
A Transformative Global R&D Collaboration July 14, 2019 12